A Glucose Metabolism‐Modulatory Nanobiohybrid Vaccine Platform Promotes Anti‐Tumor Immunity by Orchestrating Autophagy‐Dependent Cross‐Presentation and H 2 S‐Enhanced NLRP3 Inflammasome Signaling
Advanced Science · 2026
DOI: 10.1002/advs.76654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Weidong Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Cancer Vaccines, Autophagy, Inflammasomes. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Australia National Health and Medical Research Council.
Abstract (Originalsprache)
The clinical translation of cancer vaccines remains limited by the inability to effectively coordinate innate and adaptive immunity. Leveraging the metabolism pattern of the immune system, herein, we report a glucose metabolism‐modulatory nanobiohybrid vaccine with superior antitumor immunity via orchestrating cross‐presentation‐enhanced adaptive immunity and proinflammatory signaling‐mediated innate immunity. This nanobiohybrid vaccine is constructed by a nanoscale hydrogen‐bonded organic framework (HOF) co‐encapsulating glucose oxidase (GOx), and a model antigen, ovalbumin (OVA) (denoted OVA/GOx@HOF). OVA/GOx@HOF enables a GOx‐mediated enzyme reaction that consumes glucose and produces H 2 O 2 within dendritic cells (DCs) in controlled kinetics, which disrupts intracellular glucose metabolism and causes redox imbalance but minimally impacts cell viability. These effects induce autophagic machinery in DCs that promotes antigen cross‐presentation, thereby boosting cytotoxic T cell response. Meanwhile, through RNA sequencing, we found that OVA/GOx@HOF stimulates innate immunity through an NF‐κB signaling‐mediated and endogenous hydrogen sulfide (H 2 S)‐enhanced NLRP3 inflammasome pathway, leading to significant DC maturation. In a melanoma tumor model, this nanobiohybrid vaccine effectively inhibits tumor growth and metastasis, and can be applied to encapsulate neoantigens to generate a potent personalized cancer vaccine. Our findings suggested the remarkable potential of enzyme‐driven nanobiohybrid materials as a metabolism‐modulatory platform for cancer vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, Department of Chemistry, Fudan University, Shanghai, China.
- State Key Laboratory of Genetics and Development of Complex Phenotypes, Obstetrics and Gynecology Hospital, Children's Hospital, Fudan University, Shanghai, China.
- South Australian Immunogenomics Cancer Institute, The University of Adelaide, Adelaide, South Australia, Australia.
ORCID-Profile: Yannan Yang
Förderung
- National Natural Science Foundation of China
- Australia National Health and Medical Research Council
Zitieren
APA
Wang, W., Gong, Y., Li, J., Wu, T., Deng, M., & Yang, Y. (2026). A Glucose Metabolism‐Modulatory Nanobiohybrid Vaccine Platform Promotes Anti‐Tumor Immunity by Orchestrating Autophagy‐Dependent Cross‐Presentation and H 2 S‐Enhanced NLRP3 Inflammasome Signaling. Advanced Science. https://doi.org/10.1002/advs.76654
Vancouver
Wang W, Gong Y, Li J, Wu T, Deng M, Yang Y. A Glucose Metabolism‐Modulatory Nanobiohybrid Vaccine Platform Promotes Anti‐Tumor Immunity by Orchestrating Autophagy‐Dependent Cross‐Presentation and H 2 S‐Enhanced NLRP3 Inflammasome Signaling. Advanced Science. 2026. doi:10.1002/advs.76654
BibTeX
@article{Wang2026,
author = {Wang, Weidong and Gong, Yimin and Li, Jianing and Wu, Tianze and Deng, Mingli and Yang, Yannan},
title = {A Glucose Metabolism‐Modulatory Nanobiohybrid Vaccine Platform Promotes Anti‐Tumor Immunity by Orchestrating Autophagy‐Dependent Cross‐Presentation and H 2 S‐Enhanced NLRP3 Inflammasome Signaling},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76654}
}
EUVIMED